Printer Friendly

DURA PHARMACEUTICALS UPDATES ITS PRODUCT DEVELOPMENT EFFORTS

 SAN DIEGO, Nov. 19 ~PRNewswire~ -- Dura Pharmaceuticals Inc. (NASDAQ: DURA) today announced that, consistent with its strategy of emphasizing products in later stages of development, it has decided not to proceed with the development of the antihistamine Picumast previously licensed from Boerhinger Mannheim. The company said that despite the drug's efficacy, Picumast no longer met its development criteria in light of new information from Boerhinger Mannheim indicating a potentially longer and more expensive approval process than originally anticipated. Dura has chosen instead to redirect its resources toward other existing product opportunities with greater and more immediate market potential.
 Among late-stage pharmaceutical products, diagnostic devices, and drug delivery systems in its product pipeline, Dura plans to focus more aggressively on the development of its Dry Powder Inhaler (DPI), a unique drug delivery system that aerosolizes pharmaceuticals in dry powder formulation for propellant-free delivery to the lungs. Dura has made significant progress over the past few months validating the in vitro performance characteristics of the DPI. The new drug delivery system represents significant future market potential for Dura and is currently being tested in vitro to confirm dose-to-dose consistency and other unique characteristics. Results are expected within the next few weeks.
 Among other significant developments with its late-stage products, Dura is now preparing to initiate a confirmatory antigen challenge test on Pentyde(R) Ophthalmic Solution as requested by the Food and Drug Administration. Dura has licensed this product in North America to Bausch and Lomb.
 A statistical re-analysis of the data from the pivotal clinical trials for Pentyde Nasal Spray, pursuant to FDA comments following the March 1992 Advisory Committee meeting, is being completed. Dura expects to submit the re-analysis by year-end.
 Also, Dura is in the advanced stages of developing a digital spirometer, the Aspire(R) that will allow patients to monitor their lung function and asthmatic condition and expects to file a 510(k) marketing application in early 1993.
 Dura's strategy of acquiring and in-licensing late-stage prescription pharmaceuticals avoids the risk and expense of drug discovery and enables the company to bring products to market more quickly through its growing national field sales force.
 Dura is currently examining additional licensing opportunities that could add late-stage products to its product pipeline. Management believes that Dura's attractiveness as a licensing partner has grown because of the size of its specialty sales force.
 "Dura continues to be an attractive licensing candidate," according to Cam Garner, president and chief executive officer. "Dura expanded its product line with the recent launch of Tornalate(R) (bitolterol mesylate) Inhalation Solution 0.2 percent and the promotion of Tornalate Metered Dose Inhaler in the fast- growing beta agonist segment of the asthma market. The field sales force has increased to over 100. For the last four quarters, Dura has reported quarterly sales increases in excess of 75 percent on a year-to-year basis," Garner said.
 Dura Pharmaceuticals is a San Diego-based developer and marketer of prescription pharmaceutical products, drug delivery systems and medical devices for the diagnosis and treatment of allergies, asthma and related respiratory ailments.
 -0- 11~19~92
 ~CONTACT: James W. Newman, VP-finance and administration of Dura Pharmaceuticals, 619-457-2553~
 (DURA)


CO: Dura Pharmaceuticals Inc. ST: California IN: MTC SU:

LS-JB -- SD001 -- 2648 11~19~92 07:34 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 19, 1992
Words:541
Previous Article:CANADIAN HEALTH PROTECTION BRANCH AUTHORIZES EXPANDED ACCESS PROGRAM AND CONTROLLED CLINICAL TRAIL FOR AMPLIGEN
Next Article:OLIVIA RECORDS MAKES CRUISING HISTORY FOR LESBIANS: FIRST WOMEN'S RECORD COMPANY BECOMES FIRST WOMEN'S CRUISE COMPANY -- WITH AMAZING RESULTS
Topics:


Related Articles
DURA ANNOUNCES LAUNCH OF TORNALATE(R) INHALATION SOLUTION
DURA FOCUSES ON DEVELOPMENT OF DRY POWDER INHALER PRODUCTS AND ELECTS TO DISCONTINUE DEVELOPMENT OF PENTYDE PRODUCTS
DURA PHARMACEUTICALS ANNOUNCES PLANS TO BUILD OUT GMP FACILITY AND INITIATES PILOT STUDY OF DRYHALER WITH HUMANS
DURA PHARMACEUTICALS ANNOUNCES PROMOTIONS OF ROBERT SCHULTZ AND CLYDE WITHAM TO VICE PRESIDENT
DURA PHARMACEUTICALS REPORTS ON DRYHALER(TM) CLINICAL TRIAL AND UPDATES DEVELOPMENT PROGRESS
DURA PHARMACEUTICALS PROVIDES UPDATE ON SPIROS(TM) DEVELOPMENT PROGRAM
Dura Pharmaceuticals Signs Two Separate Agreements With Major Biotech And Pharmaceutical Companies for Development of Proteins In the Spiros(TM)...
Dura Pharmaceuticals Announces Completion of Albuterol Spiros(TM) Clinical Trials
Dura Pharmaceuticals, Inc. Files Registration Statement On Public Offering of Convertible Subordinated Notes

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters